Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality

American Journal of Clinical Pathology

Volumn 111, Issue 5, 1999, Pages 647-654

  Hacek, Donna M ^a,b   Suriano, Terra ^a,c   Noskin, Gary A ^a,d   Kruszynski, Julie ^b   Reisberg, Boris ^c,d   Peterson, Lance R ^a,b,d  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Department of Pathology   (United States)

^c Infect Contr and Prev Department   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Emerging infections; Health care delivery; Health care economics; Infection control; Molecular epidemiology; Nosocomial infection; Vancomycin resistant enterococci

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COST CONTROL; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL;

EID: 0032900216     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.5.647     Document Type: Article

References (28)

1. Haley RW, Culver DH, White JW, et al. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol. 1985;121:159-165.
2. Altman LK. Experts see need to control antibiotics and hospital infections. New York Times. March 12, 1998; section A, p 12.
3. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6:428-442.
4. O'Brien TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis. 1997;24(suppl 1):S2-S8.
5. Tenover FC, McGowan JE. Reasons for the emergence of antibiotic resistance. Am J Med Sci. 1996;311:9-16.
6. ASCP Susceptibility Testing Group. United States geographic bacteria susceptibility patterns, 1995. Am J Clin Pathol. 1996;106:275-281.
7. Bonten MJM, Hayden MK, Nathan C, et al. Epidemiology of colonization of patients and environment with vancomycin-resistant enterococci. Lancet. 1996;348:1615-1619.
8. Stosor V, Kruszynski J, Suriano T, et al. Molecular epidemiology of vancomycin-resistant enterococci: a two-year perspective. In: Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, September 13-16, 1997; Abstract 346.
9. Fang FC, McClelland M, Guiney DG, et al. Value of molecular epidemiologic analysis in a nosocomial methicillin-resistant Staphylococcus aureus outbreak. JAMA. 1993;270:1323-1328.
10. Check WA. Cracking the cases of infection clusters. CAP Today. 1996;10:14-24.
11. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis. 1996;174:529-536.
12. Peterson LR, Petzel RA, Clabots CR, et al. Medical technologists using molecular epidemiology as part of the infection control team. Diag Microbiol Infect Dis. 1993;16:303-311.
13. Noskin GA, Lee J, Hacek DM, et al. Molecular typing for investigating an outbreak of Candida krusei. Diagn Microbiol Infect Dis. 1996;26:117-123.
14. Bodnar UR, Noskin GA, Suriano T, et al. Use of in-house molecular epidemiology and full species identification for controlling spread of vancomycin resistant Enterococcus faecalis isolates. J Clin Microbiol. 1996;34:2129-2132.
15. Emori TG, Culver DH, Horan TC, et al. National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control. 1991;19:19-35.
16. Pitcher DG, Saunders NA, Owen RJ. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol. 1989;8:151-156.
17. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis (REA) typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol. 1993;31:1870-1875.
18. Keita-Perse O, Gaynes RP. Severity of illness scoring systems to adjust nosocomial infection rates: a review and commentary. Am J Infect Control. 1996;24:429-434.
19. Savor C, Pfaller MA, Kruszynski J, et al. Genomic methods for differentiating strains of Enterococcus faecium: an assessment using clinical epidemiologic data. J Clin Microbiol. 1998;36:3327-3331.
20. Samore M, Killgore G, Johnson S, et al. Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. J Infect Dis. 1997;176:1233-1238.
21. Archibald LK, Gaynes RP. Hospital acquired infections in the United States. Infect Dis Clin North Am. 1997;11:245-255.
22. Schifman RB, Howanitz PJ. Nosocomial infections. Arch Pathol Lab Med. 1994;118:115-119.
23. Noskin GA, Cooper I, Peterson LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med. 1995;155:1445-1447.
24. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis. 1997;24(suppl 1):S139-145.
25. Jarvis WR. Usefulness of molecular epidemiology for outbreak investigations. Infect Control Hosp Epidemiol. 1994;15:500-503.
26. Haley RW, White JW, Culver DH, et al. The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system. JAMA. 1987; 257:1611-1614.
27. Lupski JR. Molecular epidemiology and its clinical application. JAMA. 1993;270:1363-1364.
28. Scheckler WE, Brimhall D, Buck AS, et al. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: A consensus panel report. Am J Infect Control. 1998;26:47-60.